Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Псориаз и сердечно-сосудистая коморбидность (обзор литературы)

https://doi.org/10.33667/2078-5631-2020-6-18-21

Полный текст:

Аннотация

Псориаз – это хроническое иммунологически ассоциированное воспалительное заболевание кожи, связанное с системными сопутствующими заболеваниями, включая артрит, сердечно-сосудистые заболевания, заболевания почек, сахарный диабет и метаболический синдром. Эволюция представлений о сути данного дерматоза привела к концепции «псориатического марша»: псориаз как хроническое воспалительное заболевание ассоциируется с системным патологическим процессом. По многочисленным эпидемиологическим исследованиям, псориазом страдает до 5–7 % населения Земли с продолжающимся ростом заболеваемости, в том числе тяжелых и торпидно протекающих фенотипов, приводящих наиболее трудоспособные слои населения к инвалидизации. В последние годы все чаще возникает вопрос о состояниях, коморбидных псориазу. Дерматоз нередко сочетается с сердечно-сосудистыми заболеваниями (ССЗ), психическими нарушениями, иммунно-опосредованными заболеваниями, такими как болезнь Крона, красная волчанка. Основным фактором, способствующим формированию коморбидностей при псориазе, является общность некоторых звеньев патогенеза дерматоза и перечисленных заболеваний.

Об авторах

И. О. Смирнова
ФГБОУ ВО «Санкт-Петербургский государственный университет»; СПб ГБУЗ «Кожно-венерологический диспансер № 10 – Клиника дерматологии и венерологии»
Россия

д. м. н., проф. кафедры инфекционных болезней, эпидемиологии и дерматовенерологии; врач-дерматовенеролог

г. Санкт-Петербург



И. С. Владимирова
СПб ГБУЗ «Городской кожно-венерологический диспансер»
Россия

к. м. н., врач-дерматовенеролог

г. Санкт-Петербург



Список литературы

1. Langley R. G. Exploring new concepts in the successful management of psoriasis. J Eur Acad Dermatol Venerol. 2012 Mar; 26 Suppl 2: 1–2.

2. Потекаев Н.Н, Круглова Л. С. Пориатическая болезнь. М. 2014. 264 с.

3. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011; 20: 303–307.

4. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012; 26(suppl 2): 3–11.

5. Wu JJ, Nguyen TU, Poon KT, Herrington LJ. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012; 67: 924–930.

6. Круглова Л.С, Пушкина А. В., Хотко А. А. Псориаз и псориатическая коморбидность (обзор литературы).

7. Edson-Heredia E, Zhu B, Lefevre C, Wang M, Barrett A, Bushe CJ, et al. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. J Eur Acad Dermatol Venerol 2015; 29: 955–963.

8. Amin M1, Lee EB, Tsai TF, Wu JJ. Psoriasis and Co-morbidity. Acta Derm Venereol. 2020 Jan 30; 100 (3): adv00033. DOI: 10.2340/00015555–3387.

9. Олисова О. Ю. Псориаз: эпидемиология, патогенез, клиника, лечение. Журнал Consilium Medicum. Дерматология. – № 4. – 2010.

10. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol, 2007; 143 (12): 1493–1499.

11. Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013; 149 (10): 1173–1179.

12. Tsai TFWT, Hung ST, Tsai PI, et al. Epidemiology and comorbidities of psoriasis patients in national database in Taiwan. J Dermatol Sci. 2011; 63 (1): 40–46.

13. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 2017; 76: 377–39.

14. Davidivici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and comorbid conditions. J Invest Dermatol, 2010; 130 (7): 1785–1796.

15. Alexandroff AB, Pauriah M, Camp RD, et al. More then skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol, 2009; 161 (1): 1–7.

16. Martínez-Sales V, Vila V, Ricart JM, et al. Increased circulating endothelial cells and microparticles in patients with prosiasis. Clin Hemorheol Microcirc. 2015; 60 (3): 283–290.

17. Takeshita J, Mohler ER, Krishnamoorthy P, et al. Endothelial cell-, platelet-, and monocyte/macrophage-derive microparticles are elevated in psoriasis beyond cardiometabolic risk factors. J Am Heart Assoc. 2014: 3 (1): e000507.

18. Rose S, Stansky E, Dagur PK, et al. Characterization of immune cells in psoriatic adipose tissue. J Transl Med.2014; 12: 258.

19. Бакулев А. Л. Применение гепатопротекторов при псориазе: сравнительная клинико-лабораторная и ультрасонографическая оценка эффективности / А. Л. Бакулев, С. С. Кравченя // Вестн.дерматол. – 2010. – № 1. – С. 112–117.

20. Menter A., Papp K., Krueger G. et al. Persistence of biologic therapy in psoriatic disease: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Poster 1705 // JAAD. 2015. Vol. 72. N 5. P. AB 242.

21. Gelfand J. M., Neimann A. L. Risk of myocardial infarction in patients with psoriasis // JAMA. 2006, 296, 1735–1741.

22. Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a populationbased cohort study. Ann Rheum Dis 2015; 74: 326–332.

23. Strauss H. Zur Lehre von der neurogenen und der thyreogenen Glykosurie. Dtsch Med Wochenschr. 1897; 20: 309–312.

24. Reed WB, Becker SW, Rohde R, et al. Psoriasis and arthritis. Clinicopathologic study. Arch Dermatol. 1961; 83: 541–548.

25. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol. 1978; 99 (5): 469–475.

26. National Psoriasis Foundation. Available from: https://www.psoriasis.org/content/statistics Accessed January 14, 2019. Fernández-Armenteros JM, Gómez-Arbonés X, Buti-Soler M, Betriu-Bars A, Sanmartin-Novell V, Ortega-Bravo M, et al. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study. J Eur Acad Dermatol Venereol 2018; 33: 128–135.

27. Armstrong AW, Guerin A, Sundaram M, et al. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. J Am Acad Dermatol. 2015; 72 (6): 968–977. e2.

28. Azfar RS, Seminara NM, Shin DB, et al. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol. 2012; 148 (9): 995–1000.

29. Setty AR, Curhan, Choi HK. Obesity, waist circumference, weight change, and and the risk of psoriasis in women: Nurses’ Health Study II. Arch Int Med. 2007; 167 (15): 1670–1675.

30. Kumar S, Han J, Li T, et al. Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol. 2013; 27 (10): 1293–1298.

31. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012; 2: e54.

32. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012; 132 (3 Pt 1): 556–562.

33. Qureshi AA, Choi HK, Setty AR, et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009; 145 (4): 379–382.

34. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008; 159 (4): 895–902.

35. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013; 31 (3): 433–442.

36. Takeshita J, Wang S, Shin DB, et al. Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. JAMA Dermatol. 2015; 151 (2): 161–169.

37. Tom WL, Playford MP, Admani S, et al. Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Reveals a More Atherogenic Profile. J Invest Dermatol. 2016; 136 (1): 67–73.

38. Ma C, Harskamp CT, Armstrong EJ, et al. The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol. 2013; 168 (3): 486–495.

39. Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am. 2014 Mar; 43 (1): 1–23. DOI: 10.1016/j.ecl.2013.09.009.

40. Amstron AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013; 68 (4): 654–662.

41. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012; 132 (3 Pt 1): 556–562.

42. Gelfand JM, Neimann AL, Shinар DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296 (14): 1735–1741.

43. Joshi AA, Lerman JB, Dey AK, Sajja AP, Belur AD, Elnabawi YA, et al. Association between aortic vascular inflammation and coronary artery plaque characteristics in psoriasis. JAMA Cardiol 2018; 3: 949–956.

44. Dey AK, Joshi AA, Chaturvedi A, Lerman JB, Aberra TM, Rodante JA, et al. Association between skin and aortic vascular inflammation in patients with psoriasis: a case-cohort study using positron emission tomography/computed tomography. JAMA Cardiol 2017; 2: 1013–1018.

45. Egeberg A, Skov L, Joshi AA, Mallbris L, Gislason GH, Wu JJ, et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol 2017; 77: 650–656.

46. Haberka M, Bańska-Kisiel K, Bergler-Czop B, Biedroń M, Brzezińska-Wcisło L, Okopień B, et al. Mild to moderate psoriasis is associated with oxidative stress, subclinical atherosclerosis, and endothelial dysfunction. Pol Arch Intern Med 2018; 128: 434–439.

47. Gorga E, Scodro M, Valentini F, D’Ortona R, Arisi M, Sciatti E, et al. Echocardiographic evaluation of diastolic dysfunction in young and healthy patients with psoriasis: A case-control study. Monaldi Arch Chest Dis 2018; 88: 15–19.

48. Egeberg A, Bruun LE, Mallbris L, Gislason GH, Skov L, Wu JJ, et al. Family history predicts major adverse cardiovascular events (MACE) in young adults with psoriasis. J Am Acad Dermatol 2016; 75: 340–346.

49. Wu JJ, Joshi AA, Reddy SP, Batech M, Egeberg A, Ahlehoff O, et al. Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. J Eur Acad Dermatol Venereol 2018; 32: 1320–1326. 15.

50. Wu JJ, Guérin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate. J Am Acad Dermatol 2017; 76: 81–90. 16.

51. Wu JJ, Sundaram M, Cloutier M, Gauthier-Loiselle M, Guérin A, Singh R, et al. The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study. J Am Acad Dermatol 2018; 79: 60–68.

52. Hjuler KF, Bøttcher M, Vestergaard C, Bøtker HE, Iversen L, Kragballe K. Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis. JAMA Dermatol 2016; 152: 1114–112.

53. Bissonnette R, Harel F, Krueger JG, Guertin MC, Chabot-Blanchet M, Gonzalez J, et al. TNF-α antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study. J Invest Dermatol 2017; 137: 1638–164.

54. Mehta NN, Shin DB, Joshi AA, Dey AK, Armstrong AW, Duffin KC, et al. Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial. Circ Cardiovasc Imaging 2018; 11: e007394.

55. Shrivastava AK, Singh HV, Raizada A, Singh SK. C-reactive protein, inflammation and coronary heart disease. Egypt Heart J 2015; 67: 89–97.

56. Wu JJ, Rowan CG, Bebchuk JD, Anthony MS. Association between tumor necrosis factor inhibitor (TNFi) therapy and changes in C-reactive protein (CRP), blood pressure, and alanine aminotransferase (ALT) among patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis. J Am Acad Dermatol 2015; 72: 917–919.


Для цитирования:


Смирнова И.О., Владимирова И.С. Псориаз и сердечно-сосудистая коморбидность (обзор литературы). Медицинский алфавит. 2020;(6):18-21. https://doi.org/10.33667/2078-5631-2020-6-18-21

For citation:


Smirnova I.O., Vladimirova I.S. Psoriasis and cardiovascular comorbidity (literature review). Medical alphabet. 2020;(6):18-21. (In Russ.) https://doi.org/10.33667/2078-5631-2020-6-18-21

Просмотров: 66


ISSN 2078-5631 (Print)